Skip to Content

Fluxid Schwarz Pharma, Inc. - Treatment for Ulcers and other Gastrointestinal Conditions

Fluxid is new disintegrating tablet dosage form of famotidine indicated for the treatment of ulcers, gastroesophageal reflux disease and pathological hypersecretory conditions.

Posted: September 2004

Fluxid (famotidine) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.